The clinical core of the Indiana ACTU has the following objectives: (1) Enrollment and retention of HIV infected individuals into high priority protocols as part of the overall ACTG mission. A necessary corallary of this objective is production of high quality data which can be accrued only if the subjects are followed carefully and retained in trials for the appropriate length of time. (2) Continued evaluation of patients already enrolled in ACTG clinical trials. (3) Continued creative input into the ACTG in areas where investigators at Indiana have expertise. During the previous funding period, this has been primarily in the area of opportunistic infections with emphasis on disseminated histoplasmosis, which is endemic in Indianapolis and Pneumocystis carinii pneumonia where we have the opportunity to take advantage of tissue culture and animal model evaluation of anti- pneumocystis compounds currently being conducted on our campus. (4) Expansion of our capabilities to include evaluation of therapy for the opportunistic malignancies and dementia which accompany HIV infection. (5) Through an aggressive outreach program which includes the addition of a subunit at Methodist Hospital in Indianapolis and a possible subunit in Gary, Indiana, increased enrollment in ACTG protocols of previously under- represented populations, i.e., women, persons of color, and IVDUs. In order to accomplish this objective, the Indiana ACTU has developed extensive ties with community groups in Central Indiana and is in the process of developing similar ties in northwestern Indiana. One of our major objectives is inclusion of more minority physicians as active participants in the conduct of our trials.

Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Indiana University-Purdue University at Indianapolis
Department
Type
DUNS #
005436803
City
Indianapolis
State
IN
Country
United States
Zip Code
46202
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Haas, David W; Bradford, Yuki; Verma, Anurag et al. (2018) Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenet Genomics 28:179-187
Venuto, Charles S; Lim, Jihoon; Messing, Susan et al. (2018) Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s. Antivir Ther 23:345-351
Li, Binglan; Verma, Shefali S; Veturi, Yogasudha C et al. (2018) Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression. Pac Symp Biocomput 23:448-459
Gupta, Samir K; Yeh, Eunice; Kitch, Douglas W et al. (2017) Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s. J Antimicrob Chemother 72:2042-2048
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9

Showing the most recent 10 out of 181 publications